首页> 美国卫生研究院文献>Pulmonary Medicine >Biomarkers to Improve Diagnosis and Monitoring of Obstructive Sleep Apnea Syndrome: Current Status and Future Perspectives
【2h】

Biomarkers to Improve Diagnosis and Monitoring of Obstructive Sleep Apnea Syndrome: Current Status and Future Perspectives

机译:改善阻塞性睡眠呼吸暂停综合症的诊断和监测的生物标志物:现状和未来展望

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent episodes of upper airway collapse associated with oxygen desaturation and sleep disruption. It is proposed that these periodic changes lead to molecular variations that can be detected by assessing serum biomarkers. Studies have identified inflammatory, oxidative, and metabolic perturbations attributable to sleep-disordered breathing. Given that OSAS is associated with increased cardiovascular and cerebrovascular morbidity, the ideal biomarker should enable timely recognition with the possibility of intervention. There is accumulating data on the utility of serum biomarkers for the evaluation of disease severity, prognosis, and response to treatment. However, current knowledge is limited by data collection techniques, disease complexity, and potential confounding factors. The current paper reviews the literature on the use of serum biomarkers in OSAS. It is concluded that the ideal serum biomarker still needs to be discovered, while caution is needed in the interpretation of hitherto available results.
机译:阻塞性睡眠呼吸暂停综合症(OSAS)的特征是与氧饱和度下降和睡眠中断相关的上呼吸道反复发作。提出这些周期性变化导致可以通过评估血清生物标志物检测到的分子变化。研究已经确定了睡眠呼吸障碍引起的炎症,氧化和代谢紊乱。鉴于OSAS与心血管和脑血管发病率增加相关,理想的生物标志物应能够及时识别,并可能进行干预。关于血清生物标志物用于评估疾病严重程度,预后和对治疗的反应的实用性的数据不断积累。但是,当前的知识受到数据收集技术,疾病复杂性和潜在混杂因素的限制。本论文回顾了有关在OSAS中使用血清生物标志物的文献。结论是,仍然需要发现理想的血清生物标志物,而在解释迄今为止可获得的结果时需要谨慎。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号